INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Emerging Monoclonal Antibodies for Treatment of Various Diseases: Recent Advances

Anita Rathod[1]*, Neha Khadse[2], Anjali Rathod[3], Ashok Chopane[4], Sapna Ghuge[5], Kavita Gaikwad[6], Manisha Khandagale[7], Priyanka Deshmukh[8]

[1,2,3]Assistant Professor, Kamalprakash Pharmacy College and Research Centre, Kherda, Tq. Karanja (Lad) Dist. Washim, Maharashtra-444107.
[4]Dr. Vithalrao Vikhe Patil Foundation's College of Pharmacy, Vilad ghat, Ahmednagar Maharashtra.
[5,6,7,8]Shri Sai institute of pharmacy and research Chhatrapati sambhajinagar, Maharashtra- 431006.

ARTICLE INFO

Published: 16 Jan. 2025
Keywords:
Monoclonal antibodies, Cancer therapy, Auto immune diseases, Infectious diseases, Targeted therapy.
DOI:
10.5281/zenodo.14671974

ABSTRACT

The treatment of many illnesses, including as cancer, autoimmune conditions, and infectious diseases, has been completely transformed by monoclonal antibodies. Obstacles such immunogenicity, high production costs, restricted tissue penetration, and resistance development still exist despite their revolutionary effects. The methods of action, safety profiles, and clinical effectiveness of monoclonal antibodies are covered in this overview along with new developments and potential future paths. Advances in bio specific antibodies, antibody-drug conjugates, Nano bodies, checkpoint inhibitors, gene editing are emphasized as potential answers to existing challenges. Checkpoint inhibitors have revolutionized immunotherapy for cancer. The introduction of biosimilars has lowered prices and improved accessibility. These innovative advancements, their consequences for the treatment of illness, and potential avenues for further research are covered in this review. A detailed examination of industry trends, regulatory approvals, and clinical trial data is provided, offering insights into the changing MAB landscape. To find knowledge gaps and areas for improvement, new literature and expert comments are combined. Understanding the present situation and potential future developments of MAB treatment is aided by this review.

INTRODUCTION

Monoclonal antibodies represent a groundbreaking advancement in biomedical science and therapeutic development. These highly specific proteins, created from identical copies (clones) of a single immune cell type, are

***Corresponding Author:** Anita Rathod
Address: *Assistant Professor, Kamalprakash Pharmacy College and Research Centre, Kherda, Tq. Karanja (Lad) Dist. Washim, Maharashtra-444107.*
Email ✉: anitarathod812@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

engineered to precisely target specific antigens, making them indispensable tools in modern medicine. Since their inception in the 1970s, monoclonal antibodies have revolutionized the treatment of a wide array of diseases, including cancer, autoimmune disorders, and infectious diseases. Their journey, from discovery to widespread clinical application, is a testament to scientific innovation and their profound impact on patient care. The foundational technique for creating monoclonal antibodies was pioneered by Georges Köhler and César Milstein. Their method involves fusing a myeloma cell (a type of immortal cancer cell) with a specific B cell that produces the desired antibody. This fusion creates a hybridoma, a hybrid cell line capable of producing a uniform and specific antibody-referred to as a monoclonal antibody. Once isolated and purified, these antibodies can be utilized for therapeutic, diagnostic, or research purposes.

In recent years, monoclonal antibodies have become integral to the treatment landscape of various medical conditions. In oncology, they are employed for targeted therapies that specifically bind to cancer cells or associated proteins, minimizing damage to healthy tissues and enhancing therapeutic precision. In infectious diseases, they are used to neutralize pathogens or their toxins, offering a highly specific mechanism for combating infections. In immunology, monoclonal antibodies are designed to modulate immune responses, either by suppressing overactive immunity in autoimmune diseases or by enhancing it in conditions requiring immune activation. (1) Despite their transformative potential, the development and production of monoclonal antibodies present notable challenges. The process is highly complex, requiring advanced technology and expertise, which contributes to their high cost. Additionally, monoclonal antibody therapies can carry risks of side effects, including immune reactions and unintended interactions. Nevertheless, ongoing research and advancements in biotechnology are continually enhancing their efficacy, reducing production costs, and expanding their therapeutic applications.(2)

Monoclonal antibodies exemplify the intersection of science and medicine, offering a promising future for precision therapy and personalized medicine. As technology evolves, these powerful biological tools are poised to address an even broader spectrum of diseases, improving patient outcomes and transforming healthcare.

Development technique for monoclonal Antibodies:

- B-cell immortalization
- Hybridoma technology
- Phage display
- DNA&RNA encoded antibodies
- Transgenic animal technology
- Artificial Intelligence/machine learning
- Single B-cell technology
- Mammalian cell display
- Yeast display

Cell lines or clones derived from animals that have been vaccinated with the material under investigation produce these antibodies. Myeloma cells and B cells from the immunized animal are fused to create the cell lines (Köhler and Milstein 1975). One of two methods must be used to cultivate the cells in order to create the required mAb: either in vitro tissue culture or in vivo injection into the peritoneal cavity of a mouse that has been properly prepared (also known as mouse ascites). To get mAb with the necessary purity and concentration, additional processing of the tissue-culture supernatant and mouse ascetic fluid may be necessary. The mouse ascites technique is easily accessible, extensively known, and well-understood in many labs; however, the mice need to be closely observed in order to reduce any pain or discomfort brought on by an excessive build-up of fluid in the belly or by visceral invasion. If the

in vitro tissue-culture method were as well-known and understood as the mouse ascites method, and if it produced the necessary amount of antibody with every cell line, it would be widely used. However, in vitro methods have been costly and time-consuming in comparison to the mouse ascites method, and they frequently failed to produce the necessary amount of antibody even with expert manipulation. The success rate has risen to over 90% thanks to modern in vitro techniques, which have also decreased expenses. (1-5)



Fig 2: Production of monoclonal antibodies by different techniques.

a. To initiate an immunological response, mice are first immunized with the desired antigens in the conventional mouse hybridoma approach. Myeloma cells and harvested splenocytes are united to create hybridoma cells, which manufacture antibodies continuously. Following screening, chimeric or humanized antibodies are produced using the chosen leads. (3)
b. Phage show. Antigens of interest are chosen using a human antibody library that is exhibited by a human phage. Following three to five rounds of bio panning, ELISA is used to screen immune- positive phage clones, and DNA sequences are then examined in order to create and express human IgGs. (3)
c. Transgenic rodent. Comparable to single B cell approaches or the mouse hybridoma technique.
d. The method of the single B cell. PBMCs are produced from vaccinated or infected donors so that appropriate B lymphocytes can be isolated using flow cytometer. After RT-PCR, each B cell's VH and VL data are used to guide the production of human monoclonal antibodies (3-6)

The amount needed will depend on how the mAb is expected to be used (Marx and others 1997). Less than 0.1 g of mAb is needed for the majority of research undertakings and several analytical applications. Animal efficacy testing of novel mAb and the manufacturing of diagnostic kits and reagents both use medium-scale amounts (0.1–1 g). In this context, mAb production on a large scale is defined as more than 1 g. These greater amounts are employed for both therapeutic and standard diagnostic processes. For the identification of proteins, carbohydrates, and nucleic acids, monoclonal antibodies (mAb) have been and will remain crucial in biomedical research. Numerous chemicals that regulate cell division and replication have been clarified as a result of their utilization. Expanding our understanding of how molecular structure and function are related. Our knowledge of the host's reaction to infectious disease agents and the poisons they create, transplanted organs and tissues, spontaneously altered cells (tumors), and endogenous antigens (participated in autoimmunity) has improved as a result of these developments in basic biologic

sciences. Furthermore, mAb's exceptional specificity makes it possible to diagnose and cure illnesses in both humans and animals. Since mAb-producing hybridomas can live forever in the right conditions, using fewer animals is linked to ongoing mAb production, particularly when in vitro techniques are used. "Animals chosen for the procedure should be of appropriate species and quality and the minimum number required to obtain valid results," according to the U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training (IRAC 1983). Techniques like computer simulation, mathematical models, and in vitro biological systems must to be taken into account. It is crucial to utilize animals properly, which includes avoiding or minimizing their pain, suffering, and distress when it is in line with good scientific principles. The excessive tumor burden in animals is expressly addressed in the Guide for the Care and Use of Laboratory Animals (NRC 1996, page 10), which notes that "sometimes, protocols contain methods that have not been previously encountered or that have the potential to result in uncontrollably severe pain or discomfort. The literature, veterinarians, researchers, and other experts on the effects in animals should be consulted for pertinent, unbiased information on the methods and the goal of the study. IACUCs must make sure that approved protocols adhere to the Public Health Service Policy on Humane Care and Use of Laboratory Animals (NIH 1996, page 7), which states that "procedures with animals... avoid or minimize discomfort, distress, and pain to animals (in a way that is) consistent with sound research design." Therefore, it is the scientist's responsibility to first think about using in vitro techniques to produce mAb. The researcher may ask for authorization to employ the mouse ascites approach if the in vitro generation of mAb is neither feasible nor reasonable. However, "IACUCs must determine that (I) the proposed use is scientifically justified, (ii) methods that avoid or minimize discomfort, distress, and pain (including in vitro methods) have been considered, and (iii) the latter [refers to in vitro methods] have been found unsuitable before they can approve proposals which include the mouse ascites method" (NIH 1997). The current committee was not charged with evaluating the procedures required to create a cell line that secretes antibodies.(7-12)

2. Monoclonal Antibodies: Structure and Function:

B-cells or plasma create antibodies, also known as immunoglobulin (Ig), which have a molecular weight of about 150 kDa. They are structurally composed of two functional components: a fragmented antigen- binding (Fab) region for target antigen recognition and Fc, or a crystallisable region linked to the effector mechanism. Two polypeptide chains— two light and two heavy-joined by disulphide bonds that provide stability and stiffness make up the antibody's two functional domains. Three constant domains (CH1, CH2, and CH3) and one variable domain (VH) make up the heavy chains. One constant domain (CL) and one variable domain (VL) make up the light chain. Together with VL and CL, VH and CH1 make up the Fab region, whereas CH2 and CH3 are the two segments that make up the Fc region. Additionally, post-translational changes in antibodies, like glycosylation in the Fc domain, stabilize and alter their ability to bind to Fc receptors. (2,13)

Types of monoclonal antibodies:

1. Murine monoclonal antibodies

Mice are the complete source of these antibodies. Both the heavy and light chains' variable sections are derived from mice. The prefix "o-" or "-omab" is added to the general name to identify murine mAbs. For example, “rituximab” is a chimeric antibody that contains murine variable regions and

is used to treat certain types of lymphoma and autoimmune diseases.(14)

2. Chimeric monoclonal antibodies

Human constant regions and mouse variable regions make up chimeric antibodies. While the variable regions offer antigen specificity, the consistent sections dictate the antibody's effector actions. Chimeric monoclonal antibodies are identified by appending the suffix "- ximab" to the generic name. A chimeric antibody called "infliximab," for instance, targets tumor necrosis factor-alpha (TNF-α) and is used to treat inflammatory conditions including rheumatoid arthritis.

3. Humanized monoclonal antibodies

Only a minor amount of mouse sequence is included in the complementarity-determining regions (CDRs) of humanized antibodies, which primarily contain human sequence. Humanization lessens the immunogenicity of murine monoclonal antibodies. The suffix "- Zumba" is added to the generic name to create humanized mAbs. For instance, a humanized antibody called "trastuzumab" is used to treat breast cancer that is HER2-positive.(15)

4. Fully human monoclonal antibodies

Both in the constant and variable regions, fully human antibodies are made wholly from human sequences. They are made to be as compatible as possible with the human immune system while minimizing immunogenicity. The suffix "-umab" is added to the generic name to identify fully human mAbs. For instance, "adalimumab," a completely human antibody that targets TNF-α, is used to treat a number of autoimmune conditions, including psoriasis and rheumatoid arthritis.(16,17)

Mechanism of Action (MOA) of Monoclonal antibodies (mAbs):

Modern medicine relies heavily on monoclonal antibodies (mAbs), particularly in the fields of immunology, infectious diseases, and oncology. These modified antibodies work in a variety of ways and are made to target particular antigens, usually found on cells or pathogens. Their capacity to precisely engage and destroy targets or trigger immune effector actions to eradicate sick cells is the foundation of their therapeutic efficacy. Monoclonal antibodies have a complex mode of action (MOA), and depending on their target and design, different therapeutic antibodies use different processes.(18-26)

Antigen Neutralization:

In order to directly target pathogenic proteins or receptors implicated in disease processes, monoclonal antibodies are frequently employed. The antibody blocks the target antigen's biological function and stops it from interacting with other molecules by attaching itself to a particular epitope on the antigen.

Example:

Rituximab (Rituxan) depletes B lymphocytes by targeting their CD20. Since CD20 plays a role in B cell activation, blocking it can interfere with autoimmune processes or cancer, as is the case with diseases like rheumatoid arthritis and non-Hodgkin lymphoma. Targeting TNF-alpha, a cytokine that is essential in autoimmune conditions like rheumatoid arthritis and Crohn's disease, is infliximab (Regicide). Infliximab counteracts the pro-inflammatory effects of TNF-alpha by binding to it. (3)

Antibody-Dependent Cellular Cytotoxicity (ADCC)

Through the immune-mediated process of ADCC, the mAb attaches itself to its target on the surface of a tumor or infected cell. The antibody's Fc portion then engages with immune effector cells' Fc receptors, including neutrophils, macrophages, and Natural Killer (NK) cells. The effector cells are activated by this contact, which causes them to release cytotoxic chemicals (such granzymes and perforin) that cause the target cell to undergo apoptosis, or cell death.

Example:

Targeting the HER2 receptor, which is overexpressed in certain breast tumors, is Trastuzumab (Herceptin). Trastuzumab triggers ADCC, where immune cells eliminate HER2positive cancer cells, in addition to blocking HER2 signalling, which encourages tumor growth. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is frequently used to treat head and neck tumors as well as colorectal cancer. Cetuximab-mediated ADCC has been linked to its anticancer properties. (4) (5)

Complement-Dependent Cytotoxicity (CDC)

Monoclonal antibodies have the ability to activate the complement system, a component of the innate immune response, in addition to ADCC. A mAb can start the traditional complement cascade when it attaches to its target antigen on the cell surface. A membrane attack complex (MAC), which is created as a result of this activation, damages the integrity of the cell membrane and causes cell death.

Example:

Rituximab: In individuals with non-Hodgkin lymphoma and other disorders involving CD20-positive B cells, rituximab not only induces ADCC but also activates CDC. Obinutuzumab: A glycoengineered anti-CD20 monoclonal antibody used to treat chronic lymphocytic leukaemia (CLL) that improves CDC in addition to ADCC. (6)

Inhibition of Signaling Pathways

Certain monoclonal antibodies are made to block particular signalling pathways that aid in the development of illness. In oncology, where tumor cells frequently depend on specific signalling pathways for growth, survival, and metastasis, this is especially pertinent.

Example:

Cetuximab (Erbitux): prevents the overexpression of EGFR (epidermal growth factor receptor), which is found in a number of malignancies, including colorectal and head and neck cancers. Cetuximab inhibits the signalling that EGFR activation increases cell growth and survival, which reduces the proliferation of tumors.

Pembrolizumab (Keytruda): Blocks the interaction between T cells' PD-1 receptor and tumor cells' PD-L1. Tumors can avoid immune detection because of this interaction, which often lowers the immune response. Pembrolizumab improves the immune response by inhibiting PD-1, which enables the body to combat cancer cells more effectively. (7)

Antibody-Drug Conjugates (ADCs)

ADCs, or antibody-drug conjugates, are a type of hybrid medicine that combines the powerful lethal effects of poisons or chemotherapy with the targeting power of monoclonal antibodies. ADCs provide targeted medication delivery to cancer cells by using a linker to connect a cytotoxicchemical to a monoclonal antibody. The conjugate is internalized and the cytotoxic drug is released inside the cell, causing cell death, once the mAb attaches to the target antigen.

Example:

Ado-Trastuzumab emtansine, also known as Kadcyla, is an ADC that combines the anti- HER2 Trastuzumab with DM1, a strong cytotoxic medication that prevents microtubule function. Breast cancer that is HER2-positive is treated with it. Adcetris or benuximab vedotin, is an ADC that targets CD30 and is used to treat malignancies that are CD30 positive, including Hodgkin lymphoma. Mon methyl auristatin E (MMAE), the cytotoxic medication, alters microtubule dynamics. (10)

Emerging monoclonal antibodies:

Recent studies have demonstrated the development of monoclonal antibodies for a number of illnesses, including infectious, autoimmune, and cancerous conditions, driven by breakthroughs in antibody engineering,

combination treatments, and new mechanisms of action.(27-30)

Monoclonal antibodies for Various Diseases is as follows:

1. Cancer: Trastuzumab (Herceptin), Nivolumab (Opdivo), and Pembrolizumab (Keytruda)
2. Autoimmune Diseases: Rituximab (Rituxan), Adalimumab (Humira), and Infliximab (Remicade)
3. Infectious Diseases: Bamlanivimab (LY-CoV555), Regdanvimab (CT-P59), and Palivizumab (Synagis)
4. Neurological Conditions: Aducanumab (Aduhelm), Alemtuzumab (Lemtrada), and Natalizumab (Tysabri)

Rates of success of emerging monoclonal antibodies:

Table 1: Approval success rates for therapeutics monoclonal antibodies

Types of monoclonal antibodies	Total number of MABS	Number discontinued	Number FDA approved	Completion (%)	Approval success (%)
Humanized MABS, 1988-2006	131	53	11	49	17
Oncology humanized MABS	62	22	4	42	15
Immunological humanized MABS	45	19	5	53	21
Humanized MABS, 1988-1997	46	27	10	80	27

The comparatively high approval success rates of therapeutic mAbs-here defined as the probability that candidates pursuing clinical studies would ultimately obtain FDA approval—are a major factor in the present interest in these compounds. Compared to new chemical entities, chimeric and humanized mAbs often have greater success rates. Since humanized mAbs have been the subject of the most clinical research, they are the standard mAb type used to calculate success rates. The overall success rate for humanized mAbs that entered clinical studies between 1988 and 2006 was 17%, according to the data that is currently available (Table 1). The success rate of immunological mAbs was slightly higher (21%) than that of anticancer mAbs (15%) when the sample was stratified by therapeutic category. (2,31)

Table 2: Therapeutic monoclonal antibodies approved in United States: (2)

Generic name	US trade name	Therapeutic category
Muromab-CD3	Orthoclone OKT3	Immunological
Abciximab	ReoPro	Hemostasis
Rituximab	Rituxan	Cancer
Daclizumab	Zenapax	Immunological
Basiliximab	Simulect	Immunological
Palivizumab	Synagis	Anti-infective
Infliximab	Remicade	Immunological
Trastuzumab	Herceptin	Cancer
Gemtuzumab ozogamicin	Mylotarg	Cancer
Alemtuzumab	Campath	Cancer
Ibritumomab tiuxetan	Zevalin	Cancer

Adalimumab	Humira	Immunological
Omalizumab	Xolair	Immunological
Tositumomab-I131	Bexxar	Cancer
Efalizumab	Raptiva	Immunological
Cetuximab	Erbitux	Cancer
Bevacizumab	Avastin	Cancer
Natalizumab	Tysabri	Immunological
Ranibizumab	Lucentis	Opthalmic
Panitumumab	Vectibix	Cancer

CD, cluster of differentiation; (2)

Recent Advances in mAb Development:

Globally, unique antibody and protein synthesis services have undergone significant development and advancement since the 1960s. Scientists have created a variety of antibodies and their fragments with various architectures using potent techniques including phage display, B-cell amplification, and hybridoma technology with the aid of PCR. Due to their specificity and importance in the immune system's reaction to target antigens, monoclonal antibodies are essential. (12) Monoclonal antibodies (mAbs) have revolutionized the treatment of numerous diseases, particularly in the areas of oncology, autoimmune disorders, and infectious diseases. These biologics offer a very specialized tailored approach that reduces off-target effects because they are made to adhere to certain antigens. Recent advancements in monoclonal antibody development have improved patient outcomes, safety profiles, and efficacy while also increasing the therapeutic potential of these antibodies. This overview highlights some of the most important developments in the field of monoclonal antibodies during the past several years. (13,32)

1. **Cancer Immunotherapy: Focusing on Antigens Particular to Tumors:**

The treatment of cancer has benefited greatly by the development of monoclonal antibody therapy. Nowadays, monoclonal antibodies are employed to modify immune checkpoint circuits or target antigens specific to tumors.

- **Inhibitors of Checkpoint**: Immune checkpoint drugs, such as PD-1 inhibitors Pembrolizumab (Keytruda) and Nivolumab (OPDIVO), have demonstrated impressive clinical efficacy in treating malignancies such as renal cell carcinoma, non-small cell lung cancer, and melanoma. Through the inhibition of inhibitory signals that stop T cells from attacking cancer cells, these substances aid in the reactivation of the immune system. Nevertheless, checkpoint inhibitor resistance is still a significant problem, which has led to the creation of next-generation monoclonal antibodies that can improve effectiveness or deal with resistance mechanisms. (10,33)
- **Targeted Cancer Antigens**: There has been a notable therapeutic impact of novel monoclonal antibodies that target tumor-associated antigens (TAAs), including EGFR, CD20, and HER2. One important treatment for HER2-positive breast cancer has been Trastuzumab (Herceptin), a HER2targeted monoclonal antibody. An antibody-drug combination (ADC) called Trastuzumab deruxtecan (Enhertu) has drawn notice recently due to its increased effectiveness in treating HER2-positive breast cancer and gastric cancer (Shitara et al., 2021). (13,34)
- **Bispecific Antibodies**: These innovative antibodies are designed to attach to two different antigens at the same time, which may assist reroute immune cells—like T cells—to more efficiently target cancer cells. B-cell precursor acute lymphoblastic leukaemia (ALL) has been successfully treated with blinatumomab (Blincyto), a bispecific T-cell engager (BiTE). Clinical trials are underway for further potential bispecific antibodies that target diseases such as non-Hodgkin lymphoma and multiple myeloma. (14,35)

2. **Autoimmune Diseases: Modulating the Immune Response:**

Additionally, monoclonal antibodies have become a potent therapy option for autoimmune illnesses, in which the body's tissues are mistakenly attacked by the immune system. Monoclonal antibodies can aid in the management of chronic inflammation and the prevention of tissue damage by specifically targeting immunological mediators or immune cells.

- **Rheumatoid Arthritis**: Key treatments for rheumatoid arthritis (RA) have included drugs that target TNF-α and CD20, respectively, such as rituximab (Rituxan) and Adalimumab (Humira). With distinct modes of action, sirukumab and upadacitinib, both JAK inhibitors, are currently being assessed for their potential to enhance the therapy landscape for RA (15,36).
- **Multiple Sclerosis**: A CD20-targeting monoclonal antibody called ocrelizumab (Ocrevus) has shown promise as a treatment for multiple sclerosis (MS), especially in individuals with primary progressive MS. Clinical trials have demonstrated that ocrelizumab greatly slows the course of the disease, which is a major advancement in MS therapy (16,37).
- **Systemic Lupus Erythematous (SLE)**: The first novel medication for SLE to be licensed in over 50 years was belimumab (Benlysta), a monoclonal antibody that suppresses B lymphocyte stimulator (BLyS). Since its approval, there has been an increase in interest in creating more focused treatments for this intricate autoimmune condition (17,38).

3. **Infectious Diseases: From HIV to COVID-19:**Treatment of several infectious disorders, particularly viral infections, has shown encouraging outcomes with monoclonal antibodies.

- **HIV:** Antiretroviral medications have historically been the mainstay of HIV treatment; nevertheless, monoclonal antibodies are currently being investigated as long-acting treatments. 2018 saw the approval of Ibalizumab, a monoclonal antibody that targets CD4 cells, as a rescue treatment for HIV that is resistant to multiple drugs. Furthermore, as part of therapeutic vaccine techniques, bavencio (avelumab) is being researched in relation to HIV (18,39).
- **COVID-19**: During the COVID-19 pandemic, monoclonal antibodies against SARS- CoV-2 developed quickly, demonstrating their potential for treating viral diseases. To prevent and treat COVID-19 infection, sotrovimab, Bamlanivimab, and casirivimab and imdevimab (REGEN-COV) were created and approved for use in emergency situations. Ongoing study and modification are necessary, though, as the advent of viral variations like Delta and Omicron has raised doubts over the neutralizing effectiveness of these monoclonal antibodies (19,40).

Clinical Efficacy and Safety:

- **Effectiveness:** In numerous clinical trials, monoclonal antibodies have demonstrated a modest level of effectiveness, especially in the treatment of COVID-19, autoimmune disorders, and specific cancer types. For example, sotrovimab and BRII-196 + BRII-198, anti-SARS-CoV-2 neutralizing monoclonal antibody treatments, have shown strong suppression of SARS-CoV-2 replication. Likewise, monoclonal antibodies that target IL- 4Rα, IL-5, and IgE have demonstrated therapeutic benefit in treating nasal polyposis and chronic rhino sinusitis. (20,41,42)
- **Safety:** Monoclonal antibodies have a relatively positive safety profile, with the majority of side effects being minor and transient. Serious side effects, including hepatotoxicity, cardiac arrhythmias, and allergy, are possible, but. Throughout therapy, it's critical to keep a careful eye on patients and report any side effects right once (20,43).
- **Clinical Pharmacology:** Clinical pharmacology is essential to the development of monoclonal antibody drugs. To guarantee the best possible efficacy and safety, this involves assessing pharmacokinetics, pharmacodynamics, and dosage response. (21)
- **Management and Detection:** In order to avoid interfering with laboratory tests, clinicians should be aware that therapeutic monoclonal antibodies may be detected. To reduce side effects and maximize therapeutic results, meticulous management and routine monitoring are required. (22,44)

Safety Concerns:

1. Immunogenicity, such as antibodies to drugs
2. Antibodies that neutralize
3. Endogenous protein cross-reactivity
4. Cardiovascular events, such as those caused with Pembrolizumab
5. Neurological occurrences (such as neuropathy linked to Nivolumab)

Regulatory Guidelines:

1. FDA Industry Guidance: 2019 Monoclonal Antibodies (25,45)
2. The 2020 EMA Monoclonal Antibody Guideline (25,46)

Safety Profile:

The following are typical adverse reactions (ARs) linked to monoclonal antibodies:

1. **Reactions of infusion**: Infusion responses frequently happen following initial dosing29–31, although they can be controlled by identifying risk factors, doing adequate monitoring, and acting quickly. Some mAbs can cause TlS, CRS, and systemic inflammatory response syndrome in first-dose infusion reactions. Rituximab (Rituxan/MabThera; Genentech, Biogen Idec) is an example of a chimeric CD20-specific mAb33. Premedication, cautious gradual increases in the rate of infusion, and proper hydration and diuresis can all help to minimize these first effects.(65) (Trevor T. Hansel)
2. **Infections**: A well-known adverse impact of some monoclonal antibodies is infectious illnesses, which are indicative of acquired immunodeficiency and are typically brought on by the loss of the mAb's target ligand. In fact, specific illnesses show how the target ligand protects the body in a healthy immune system and shed light on how this protein works against specific viruses. (47-48)
3. **Cancers** (such as solid tumors and lymphomas): Like other immunosuppressive drugs, some mAbs can accelerate the growth of tumors rather than removing too many cancerous cells at once. There is ongoing debate over the relationship between TNF-specific mAb (infliximab) therapy and an elevated risk of cancer. According to a recent analysis of 3,493 individuals treated with TNF-specific mAbs, patients with rheumatoid arthritis had a dose-dependently higher chance of developing cancer. Nonetheless, rheumatoid arthritis patients receiving TNF-specific mAbs have a comparable risk of solid tumors to previous cohorts132. Furthermore, there is no increased risk of cancer when comparing national registries of rheumatoid arthritis patients receiving TNF-specific mAbs with those on methotrexate. However, after prolonged usage, methotrexate also impairs immunological function, which may lead to cancer. Although there have been reports of an elevated risk of lymphomas in individuals with inflammatory bowel disease on infliximab, a direct causal link has not been established134. It has been demonstrated that infliximab increases the risk of cancer in 79 patients with chronic obstructive pulmonary disease (in those who have smoked heavily)135. Additionally, infliximab treatment in young children with inflammatory bowel disease has been linked to hepatosplenic T-cell lymphoma.
4. **Autoimmune diseases:** mAbs can induce a number of autoimmune diseases, some of which are listed below, by their immunomodulatory effects, which include Immunosuppression. Drug-induced lupus and lupus-like symptoms, Thyroid disorders, Colitis autoimmune. (Trevor T. Hansel)

Challenge and future direction for the monoclonal antibodies:

In the treatment of many illnesses, especially cancer, autoimmune conditions, and infectious diseases, monoclonal antibodies (mAbs) have become essential. But using them presents a number of difficulties and issues for further research.

❖ **Challenges:**

1. **Immunogenicity**: Patients may experience allergic reactions or a decrease in the effectiveness of treatment if monoclonal antibodies, especially those originating from non-human sources, cause immunological reactions. Although completely human or humanized antibodies are intended to reduce this problem, immunogenicity is still a problem, particularly for biosimilars. (10,49)
2. **Cost and Accessibility**: Monoclonal antibodies are costly to generate due to the intricate

procedures involved, such as hybridoma creation and recombinant DNA technology. Access to patients is restricted by the high cost, particularly in places with limited resources (23,50).

3. **Limited Tissue Penetration**: Because monoclonal antibodies are usually big molecules, they can't go very deep into tissues, especially in solid tumors. This may make them less successful in treating infections or some types of cancer if the target cells are deeply ingrained. (24,51)
4. **Development of Resistance**: In oncology, several cancers become resistant to monoclonal antibodies by the activation of alternate pathways or mutations in the target antigen. This restricts the therapies' long-term efficacy and calls for the creation of combination therapies. (11,52)
5. **Adverse Effects**: Although monoclonal antibodies are frequently thought to be safer and more specific than conventional chemotherapy, adverse effects are nevertheless possible. Depending on the target, they can include organ-specific toxicities, cytokine release syndrome, or infusion responses. (6,53)
6. **Target Limitation**: Not all illnesses have distinct biochemical targets that can be targeted by monoclonal antibodies. For example, the creation of functional monoclonal antibodies may be challenging in autoimmune illnesses due to the involvement of many targets or complex immune system deregulation.
7. **Production and Scaling**: It is difficult and expensive to produce monoclonal antibodies on a large scale. For the industry, producing a reliable, high-quality product in big quantities is still difficult.(54-55)

Future Directions:

1. **Bispecific Antibodies**: By more efficiently rerouting immune cells to target tumor cells, bispecific antibodies-which can bind to two distinct antigens at once—have the potential to be beneficial in the treatment of disorders like cancer. Some of the drawbacks of single-target monoclonal antibodies might be addressed by this (26).
2. **Antibody-Drug Conjugates (ADCs):** Monoclonal antibodies connected to cytotoxic medications are known as ADCs. These medications can minimize harm to healthy cells by specifically delivering targeted therapy to cancer cells. This strategy has a lot of potential for oncology and could get beyond monoclonal antibodies' drawbacks by directly cytotoxically attacking tumor cells. (27)
3. **Nano-bodies**: Compared to conventional antibodies, these smaller camelid-derived antibody fragments provide superior tissue penetration and stability. Targeting hard-to- reach areas like the brain or solid tumors may be a specific application for Nano bodies.(28)
4. **Checkpoint Inhibitors and Immune Modulation**: In cancer immunotherapy, combining monoclonal antibodies with immune checkpoint inhibitors (such as PD-1/PD- L1 inhibitors) is a promising approach. For patients who do not react to individual treatments, this combination may assist enhance response rates and overcome tumor- induced immune evasion. (27)
5. **Gene Editing for Customized Therapies:** More specialized mAb treatments could be made possible by developments in CRISPR and gene-editing technology. Depending on a patient's genetic profile, these could target particular mutations or tailor therapy. (29)
6. **Next-Generation Bio-similar:** The creation of biosimilars-similar but distinct versions-is becoming more and more crucial as the patents on some monoclonal Antibodies expire. Despite ongoing safety and effectiveness issues, they have the potential to lower prices and increase patient access to monoclonal antibody medicines. (30)
7. **Improved Target Discovery**: Developments in high-throughput screening, bioinformatics, and artificial intelligence will probably influence mAb therapy in the Future because they can find new therapeutic targets, including those for illnesses for which there are now no antibody therapeutics. (30)
8. **Improved Manufacturing Technologies**: With the use of technology such as improved cell lines, cell-free expression methods, and improved bioreactors, bio manufacturing is constantly evolving. By lowering production costs and

boosting scalability, these developments hope to lower the cost and expand the accessibility of monoclonal antibodies. The following are some obstacles and potential paths for monoclonal antibodies: (6)

9. **Emerging Trends:** (31)

1. Creating antibodies with better qualities by synthetic antibody technology.
2. Targeted chemotherapy using antibody-drug conjugates (ADCs).
3. Immunocytokines: Mixing cytokines and monoclonal antibodies.
4. Using monoclonal antibodies to target the micro biome: Changing the micro biome for medical purposes.

CONCLUSIONS:

Although there are still issues, monoclonal antibodies have shown notable therapeutic benefit in a number of disorders. Promising answers to these problems can be found in emerging trends and technologies. Subsequent investigations ought to concentrate on refining the design of monoclonal antibodies, enhancing production procedures, and investigating combination treatments. The effectiveness and safety of monoclonal antibodies may be further improved by personalized medicine techniques that make use of gene editing and precision targeting. Monoclonal antibodies are positioned to continue to be a mainstay of contemporary medicine as the science develops, giving patients all over the world fresh hope.It is obvious that these targeted therapies will become more and more significant in the treatment of a variety of illnesses as the field of monoclonal antibodies develops. Monoclonal antibodies' noteworthy therapeutic advantages in a variety of clinical trials and real-world situations highlight their potential to improve patient outcomes. With new trends and technology providing creative answers to existing constraints, the development of monoclonal antibodies has a bright future. Researchers and doctors can fully realize the potential of these therapeutics by concentrating on improving production processes, improving antibody design, and investigating combination treatments. These tailored medicines will probably become more and more significant in the treatment of many ailments as a result of further research and development. In the end, monoclonal antibodies have a promising future and the ability to significantly improve the lives of millions of patients worldwide.

Conflicts Of Interests:

All authors have declared no conflict of interest.

REFERENCES

1. Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495–497. https://doi.org/10.1038/256495a0
2. Jain, R. K. (1994). Barriers to drug delivery in solid tumors. Scientific American, 271(1), 58–65. https://doi.org/10.1038/scientificamerican0794-58
3. Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine, 6(4), 443–446. https://doi.org/10.1038/74704
4. Ghetie, M. A., & Vitetta, E. S. (2001). Immunotoxins and antibody-drug conjugates for cancer treatment. Current Opinion in Investigational Drugs, 2(11), 1582–1588.
5. Reichert, J. M. (2002). Monoclonal antibodies: A review of the landscape. Journal of Clinical Immunology, 22(2), 67–74. https://doi.org/10.1023/A:1014891314755.
6. Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009). Therapeutic antibodies: Successes, limitations, and hopes for the future. British Journal of Pharmacology, 157(2), 220–233. https://doi.org/10.1111/j.1476-5381.2009.00190.x
7. Adams, G. P., & Weiner, L. M. (2005). Monoclonal antibody therapy of cancer. Nature Biotechnology, 23(9), 1147–1157. https://doi.org/10.1038/nbt1137
8. Hynes, R. O. (2002). Integrins: Bidirectional, allosteric signaling machines. Cell, 110(6),

673–687. https://doi.org/10.1016/S0092-8674(02)00971-6

9. Scott, A. M., Wolchok, J. D., & Old, L. J. (2012). Antibody therapy of cancer. Nature Reviews Cancer, 12(4), 278–287. https://doi.org/10.1038/nrc3236
10. Carter, P. (2001). Improving the efficacy of antibody-based cancer therapies. Nature Reviews Cancer, 1(2), 118–129. https://doi.org/10.1038/35101072
11. Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495–497.
12. Jain, R. K. (1999). Barriers to drug delivery in solid tumors. Scientific American, 286(1), 58–65.
13. Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine, 6(4), 443–446.
14. Ghetie, M. A., & Vitetta, E. S. (2001). Immunotoxins and antibody-drug conjugates for cancer treatment. Current Opinion in Investigational Drugs, 2(11), 1582–1588.
15. Reichert, J. M. (2002). Monoclonal antibodies: A review of the landscape. Journal of Clinical Immunology, 22(2), 67–74.
16. Di Gaetano, N., Cittera, E., Nota, R., Vecchio, V., Grieco, V., & Neri, T. M. (2003). Complement activation determines the therapeutic activity of rituximab in vivo. Journal of Immunology, 171(3), 1581–1587.
17. Carter, P. (2006). Monoclonal antibodies in cancer therapy. In The Oncology Drug Handbook (pp. 235–248).
18. Larrick, J. W., & Bouncier, D. L. (2007). Monoclonal Antibodies: Principles and Practice.
19. Scheinberg, D. A., et al. (2008). Radioimmunotherapy with monoclonal antibodies. Cancer Immunotherapy and Immunobiology, 48(5), 737–742.
20. Wang, W., & Singh, S. (2009). Antibody aggregation and stability: Mechanisms and formulation. The Journal of Pharmaceutical Sciences, 98(9), 3452–3469.
21. Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010). Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery, 9(10), 767–774.
22. Schroeder, H. W., & Cavacini, L. (2010). Structure and function of immunoglobulin. The Journal of Allergy and Clinical Immunology, 125(2), S41–S52.
23. Liu, L., et al. (2010). Mechanisms of action of monoclonal antibodies in cancer therapy. Journal of Clinical Oncology, 28(28), 4206–4217.
24. Furie, R., Khamashta, M. A., & Merrill, J. T. (2011). Belimumab in systemic lupus erythematosus—final results of a phase III, multicenter, randomized, placebo-controlled study. Arthritis & Rheumatism, 63(5), 1220–1230.
25. Scott, A. M., et al. (2012). The role of monoclonal antibodies in the treatment of cancer. Cancer Immunology, Immunotherapy, 61(3), 303–314.
26. Shuptrine, C. W., et al. (2012). Monoclonal antibody therapeutics in oncology: Advances and challenges. Cancer Immunology, Immunotherapy, 61(11), 1795–1804.
27. Topalian, S. L., Hodi, F. S., Brahmer, J. R., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443–2454.
28. Younes, A., et al. (2016). Brentuximab vedotin: An innovative antibody–drug conjugate for the treatment of Hodgkin lymphoma and other CD30-positive malignancies. Blood, 128(3), 289–295.

29. Chen, D. S., & Mellman, I. (2017). Oncology meets immunology: The cancer-immunity cycle. Immunity, 39(1), 1–10.
30. Hauser, S. L., et al. (2017). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, 376(3), 221–234.
31. Kraemer, M. J. W., & Dübel, S. (Eds.). (2018). Monoclonal Antibodies: Methods and Protocols.
32. Kuron, G. R., et al. (2018). Monoclonal antibody-based cancer therapeutics. Nature Reviews Drug Discovery, 17(5), 311–327.
33. Wei, S. C., Duffy, C. R., & Allison, J. P. (2018). Fundamentals of immune checkpoint blockade and the regulatory mechanisms that modulate the efficacy of immune checkpoint inhibitors. Nature Reviews Immunology, 18(3), 145–150.
34. Gulick, R. M., et al. (2018). Long-acting monoclonal antibodies for the treatment of HIV-1 infection. The Lancet, 391(10122), 2556–2567.
35. Scott, A. M., Wolchok, J. D., & Old, L. J. (2012). Antibody therapy of cancer. Nature Reviews Cancer, 12(4), 278–287. https://doi.org/10.1038/nrc3236
36. Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2020). Antibodies to watch in 2020. mAbs, 12(1), 1703531. https://doi.org/10.1080/19420862.2019.1703531
37. Weiner, L. M., Murray, J. C., & Shuptrine, C. W. (2012). Antibody-based immunotherapy of cancer. Cell, 148(6), 1081–1084. https://doi.org/10.1016/j.cell.2012.02.034
38. Lu, R. M., Hwang, Y. C., Liu, I. J., Lee, C. C., Tsai, H. Z., Li, H. J., & Wu, H. C. (2020). Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 27(1), 1–30. https://doi.org/10.1186/s12929-020-0639-1
39. Barrow, A. D., & Trowsdale, J. (2008). The extended human leukocyte receptor complex: Diverse ways of modulating immune responses. Immunological Reviews, 224(1), 98–123. https://doi.org/10.1111/j.1600-065X.2008.00664.x
40. Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009). Therapeutic antibodies: Successes, limitations, and hopes for the future. British Journal of Pharmacology, 157(2), 220–233. https://doi.org/10.1111/j.1476-5381.2009.00190.x
41. Reichert, J. M. (2011). Antibodies to watch in 2011: Data and trends from the clinical trials. mAbs, 3(1), 76–99. https://doi.org/10.4161/mabs.3.1.14120
42. Strohl, W. R., & Knight, D. M. (2009). Discovery and development of biopharmaceuticals: Current issues. mAbs, 1(1), 26–36. https://doi.org/10.4161/mabs.1.1.7018
43. Reichert, J. M. (2008). Monoclonal antibodies as innovative therapeutics. Nature Reviews Drug Discovery, 7(4), 327–338. https://doi.org/10.1038/nrd2399
44. Carter, P. J., & Lazar, G. A. (2018). Next-generation antibody therapeutics. Nature Reviews Drug Discovery, 17(3), 197–223. https://doi.org/10.1038/nrd.2017.227
45. Adair, J. R., Siegel, J. P., & Pluznik, D. H. (2010). Therapeutic applications of monoclonal antibodies in cancer treatment. Expert Opinion on Biological Therapy, 10(6), 895–907. https://doi.org/10.1517/14712591003776800
46. Harms, B. D., Kearns, J. D., & McKean, D. (2015). Engineering monoclonal antibodies for improved therapeutic utility. Methods in Molecular Biology, 1286, 125–148. https://doi.org/10.1007/978-1-4939-2450-9_6

47. Ecker, D. M., Jones, S. D., & Levine, H. L. (2015). The therapeutic monoclonal antibody market. mAbs, 7(1), 9–14. https://doi.org/10.4161/19420862.2015.989042
48. Chan, A. C., & Carter, P. J. (2010). Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology, 10(5), 301–316. https://doi.org/10.1038/nri2761
49. Aggarwal, S. (2014). Targeted therapy in cancer: Opportunities and challenges. mAbs, 6(2), 14–19. https://doi.org/10.4161/mabs.27338
50. Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010). Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery, 9(10), 767–774. https://doi.org/10.1038/nrd3229
51. Tedesco, D., & Jarvis, P. (2010). Antibody-drug conjugates: An emerging class of cancer therapeutics. OncoTargets and Therapy, 3, 471–479. https://doi.org/10.2147/OTT.S10807
52. Wang, L., Amphlett, G., Blättler, W. A., Lambert, J. M., & Zhang, W. (2005). Structural characterization of a potent antibody-drug conjugate. Bioconjugate Chemistry, 16(2), 397–405. https://doi.org/10.1021/bc0497634
53. Smith, K. A., & Reid, E. C. (2015). Advances in antibody engineering for cancer therapy. Antibody Therapeutics, 8(3), 295–303. https://doi.org/10.1093/abt/8.3.295
54. Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017). Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews Drug Discovery, 16(5), 315–337. https://doi.org/10.1038/nrd.2016.268
55. Jefferis, R. (2009). Glycosylation as a strategy to improve antibody-based therapeutics. Nature Reviews Drug Discovery, 8(3), 226–234. https://doi.org/10.1038/nrd2804

HOW TO CITE: Anita Rathod*, Neha Khadse, Anjali Rathod, Ashok Chopane, Sapna Ghuge, Kavita Gaikwad, Manisha Khandagale, Priyanka Deshmukh, Emerging Monoclonal Antibodies for Treatment of Various Diseases: Recent Advances, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 1, 1309-1323. https://doi.org/10.5281/zenodo.14671974